CPHI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Login
View profile
Log out
Welcome back

Click below to sign in and see leads, RFIs or statistics

Sign in

Sign out
- Search Impressions
  
  3 287
- Page views
  
  324
- Request for information
  
  54
Subscribe

AGC Biologics

About AGC Biologics

The AGC Life Science Company was established as a division within AGC Group and it operates ten CDMO facilities worldwide. The group's core focus is on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients, and agrochemicals. This group also provides research and development of new drugs and manufacturing for high-performance fluorine compounds.

Sales Markets

East Asia (e.g. China, Japan, Korea)
Europe - EU countries
North America (USA, Canada)

Categories

Contract Development and Manufacturing Organisations (CDMOs) and Contract Manufacturing Organisations (CMOs) (Services) Contract Manufacturing

AGC Biologics

US
2018

On CPHI since
1000 - 4999

Employees

Compare

Add to favorites Added to favorites

Company types

CMO/CDMO

Primary activities

Contract Manufacturer

Contact info

(202) 725-4202

Meet us at

CPHI Americas 2025

Pennsylvania Convention Center, Philadelphia

20 May 2025 - 22 May 2025

View Exhibitor Profile

AGC Biologics Resources (3)

News AGC Biologics to increase capacity for pDNA and mRNA manufacturing in Heidelberg

The expansion plans include an additional manufacturing line, a new cleanroom and a new process development lab

14 Sep 2021
News AGC Biologics and Rocket Pharma expand LVV manufacturing partnership

The expanded agreement will ensure Rocket Pharma's supply of lentiviral vectors across its pipeline

20 Apr 2021
News AGC Biologics becomes first manufacturer of newly approved Libmeldy

The CDMO will use its gene and cell therapy commercial expertise to bring "remarkable innovation" to young eligible patients

4 Jan 2021